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Abstract
Background Osteogenesis imperfecta (OI) is the most common inherited disorder of bone fragility in children, increasing 
fracture risk 100-fold and can feature dental and facial bone involvement causing additional morbidities.
Aim To assess the utilisation of tertiary dental services by children and young people with OI attending a supra-regional 
multi-disciplinary OI service and review of the pathology identified and interventions undertaken.
Design Case notes review of the current caseload of children and young people (0–18 years) with OI at a large regional OI 
specialist centre (n = 92). Primary outcome was whether an initial dental assessment was arranged in a tertiary dental centre 
and the corresponding attendance.
Results 49% had a tertiary dental assessment arranged, of whom 82% attended (one quarter requiring several appointments) 
and 18% did not attend (DNA).Those travelling > 100 miles had a DNA rate of 47%. Assessed children had dentinogenesis 
imperfecta (24%, 50% in Type III OI), radiographs (95%), caries (41%), required extraction under general anaesthesia (38%) 
and malocclusion (30%). 48% of the total cohort received bisphosphonates.
Conclusion Tertiary dental assessment encountered barriers to uptake of recommended referral in all patients, often due to 
geographic factors of travel distance, yet when implemented did identify pathology in a large proportion and many resulted in 
dental intervention. These emphasise the relevance of specialist dental assessment in OI, particularly in the modern context 
of increased use of bisphosphonates. This is challenging to achieve and several models of delivery of care may need to be 
considered in this chronic childhood condition.
Keywords Osteogenesis imperfecta · Dentinogenesis imperfecta · Bisphosphonate therapy · Dental caries · Tertiary dental 
assessment
Introduction
Osteogenesis imperfecta (OI) is a collagen disorder predomi-
nantly characterised by bone fragility leading to fractures 
but also affects dentition (Trejo and Rauch 2016). The over-
all estimated incidence is 1 in 15,000 births. Classification 
remains based on the original ‘Sillence’ system grouped 
according to severity: Type I mild–moderate, Type III severe 
and Type IV OI intermediate severity, whilst Type II is fre-
quently fatal perinatally (Sillence et al. 1979). The classifica-
tion system has since been extended to include Type V with 
its distinctive radiographic appearance and additional OI 
types reflect identification of newer molecular mechanisms 
(Van Dijk and Sillence 2014). The Sillence classification 
was originally based on clinical and radiograph features; 
however, with new genetic discoveries the classification has 
evolved and a new genetic classification has been established 
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to incorporate a new type of OI for each genetic defect iden-
tified (Marini and Blissett 2013). The Sillence numeration 
has, however, been continued for each new genetic defect 
discovered and as such there are currently more than 16 dif-
ferent types of OI (Forlino and Marini 2016). The current 
classification is demonstrated in Table 1.
The predominant skeletal collagen is Type I collagen, 
formed of two A1 chains and one A2 chain (encoded by 
COL1A1 and COL1A2 genes, respectively) (Trejo and Rauch 
2016). Mutations in these two large genes underlie 90% of 
OI cases and the resulting defective proteins give abnormal 
bone matrix, causing bone fragility, fractures and skeletal 
deformity (Imbert et al. 2014; Forlino and Marini 2016). The 
overall risk of fracture can be up to 100-fold greater than 
the general population, although this varies greatly between 
individual patients as severity is highly variable (Ben Amor 
et al. 2013), with fractures most commonly in vertebrae, ribs 
and upper and lower limbs (Forlino and Marini 2016). Skel-
etal deformities include a long bone bowing, kyphoscoliosis 
and chest wall deformities. Extra-skeletal features include 
blue sclera, hearing impairment and dentinogenesis imper-
fecta (DI) (O’Connell and Marini 1999).
Dentinogenesis imperfecta (DI) occurs either as a com-
ponent of OI, or as a distinct entity. It is characterised by an 
abnormal dentine structure in deciduous dentition alone or 
in both deciduous and permanent dentitions (Barron et al. 
2008), although noticeably more severe in the deciduous 
dentition [O’Connell and Marini, 1999]. DI has an incidence 
of 1 in 8000 and can be categorised using Shields classifica-
tion criteria (Shields et al. 1973). Shields Type I occurs in 
OI with COL1A1 or COL1A2 gene mutations that result in 
disruption of the organic dentine phase, rich in type I col-
lagen (Sapir and Shapira 2007). The more prevalent Shields 
type II is separate from OI and is instead due to dentine sial-
ophosphoprotein (DSPP) gene mutations (Sapir and Shapira 
2007).
Approximately 50% of children with OI will have dental 
abnormalities of some degree (Patel et al. 2015). Clinically, 
teeth appear opalescent with grey or yellow–brown hue due 
to defective dentine (Patel et al. 2015). Radiographically, 
crowns appear overtly bulbous with marked cervical narrow-
ing, shortened roots and pulp obliteration (Patel et al. 2015). 
As the enamel usually appears normal, the degree of attrition 
is very variable and the rate of tooth tissue loss correlates 
with DI severity (O’Connell and Marini 1999). In addition, 
skeletal and dental alveolar malocclusion is more prevalent 
in OI than the normal population; severity of malocclusion 
correlates with OI severity (Jensen and Lund 1997).
Paediatric medical treatment includes the now established 
role of bisphosphonates. The combination of fragile bones 
with recurrent fractures and weakened muscles provides a 
challenge for patients to attain and maintain gross motor 
skills. Physical rehabilitation is this crucial to help maintain 
function and independence (Engelbert et al. 2004). Place-
ment of intra-medullary telescoping rods into long bones 
can be used to stabilise severe fractures and provide support 
for healing following correction of bony deformities (Espos-
ito and Plotkin 2008). Since the first research use almost 
50 years ago, long-term data on dental development and 
treatment are emerging and are reassuring, although height-
ened dental surveillance remains important (O’Connell and 
Marini 1999).
OI care is highly multi-disciplinary, coordinated across 
several specialties. Multi-disciplinary care for children with 
Severe, Complex or Atypical OI was nationally commis-
sioned across England in 2011, with four supraregional 
centres. The University Hospitals Bristol (UHB) Highly 
Specialised OI centre is a large service receiving referrals 
from South West England and Wales. The clinical recom-
mendation was for all OI children to receive a formal dental 
assessment, ideally in tertiary care, with the referral made 
by the medical team. This is provided by the Bristol Dental 
Hospital paediatric clinic, co-located on the same precinct as 
the UHB OI service, which receives referrals from primary 
dental services and from paediatric specialist services for 
children with a range of chronic conditions from across the 
region.
Service review of the tertiary care dental assessments for 
OI patients was initiated following clinical impression of 
variable uptake of dental appointments. Our review exam-
ined rates of attendance and barriers, dental pathology and 
interventions to inform best model of care that was feasible 
and appropriate for the morbidity in childhood OI.
Table 1  Classification of osteogenesis imperfecta
OMIM Online Mendelian inheritance in man
OMIM Sillence classification Genetic defect
166,200 Type I COL1A1/A2
166,210 Type II COL1A1/A2
259,420 Type III COL1A1/A2
166,220 Type IV COL1A1/A2
610,967 Type V IFITM5
613,982 Type VI SERPINF1
610,682 Type VII CRTAP
610,915 Type VIII LEPRE1/P3H1
259,440 Type IX PPIB
613,848 Type X SERPINH1
610,968 Type XI FKBP10
613,849 Type XII SP7
614,856 Type XIII BMP1
615,066 Type XIV TMEM38B
615,220 Type XV WNT1
616,229 Type XVI CREB3L1
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Methodology
A retrospective case note analysis was conducted for all 
children with OI aged ≤ 18 years currently attending the 
University Hospital Bristol (UHB) OI Service.
The primary outcome was whether an initial dental 
assessment was arranged at the Bristol Dental Hospital 
(BDH) and whether this was attended. Factors that could 
impact tertiary dental service provision were recorded: 
distance from the clinic, OI severity and previous dental 
experience. The second component was analysis of the 
types of dental issues and interventions experienced by 
the OI cohort in primary, secondary and tertiary care.
A data collection proforma was constructed and data 
were collected retrospectively from hospital electronic 
records: patient cohort from UHB OI database cross-
referenced against the BDH data,  Medway® system for 
appointments and attendance and  Evolve® patient elec-
tronic medical record, which included scanned historical 
paper records, clinic letters and investigation results. A 
preliminary search of the electronic records was con-
ducted using pre-determined keywords (Appendix 1) 
followed by an in-depth analysis. In the few cases where 
the electronic record contained insufficiently detailed 
dental record, the BDH paper notes were sourced.
With regard to dental pathologies, caries was diag-
nosed following clinical and radiographic assessment. 
The skeletal relationship was determined from clini-
cal assessment alone. The diagnosis of dentinogenesis 
imperfecta (DI) was made from a combination of clinical 
appearance and the radiographic findings.
Results
The cohort comprised 92 patients: 57% male; age mean 9 
(range 8 months–18 years) years. Distribution of cohort was 
Type I OI (91%, n = 83), Type III OI (6%, n = 6), Type IV OI 
(2%, n = 2) and Type V OI (1%, n = 1).
The recommended standard was that all paediatric cases 
of OI should undergo a dental assessment in tertiary care as 
an outcome from the multi-disciplinary OI clinic consulta-
tion. 51% (n = 47) of the cohort did not have a dental assess-
ment arranged at the BDH (Fig. 1). Of the 49% (n = 45) who 
Fig. 1  The percentage of OI patients who received an initial dental assessment in tertiary care along with the percentage attendances and DNA 
rate of the initial assessment
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had an initial assessment arranged, 82% (n = 37) attended 
an assessment, while 18% (n = 8) did not ever attend despite 
several offered appointments. Non-attendance also occurred 
amongst the 37 who were assessed: 73% (n = 27) attended 
the first assessment appointment made, 25% (n = 9) did not 
attend a first appointment but did attend a second booked 
appointment, while one individual (2%) only attended a third 
attempt (Fig. 1).
Distance from patient’s home to UHB was mean 50 
(range 4–183) miles. The mean distance travelled by those 
who attended the initial dental assessment was 39 miles. 
However, the mean distance for those who failed to attend 
the initial assessment was 49 miles. The OI cohort was 
grouped according to the distance travelled to UHB. The 
largest group travelled less than 10 miles (n = 24) with the 
second largest travelling greater than 100 miles (n = 16) 
(Table 2).
The DNA rate for the initial dental assessment and for 
all other dental appointments was analysed against distance 
travelled (Table 1). The DNA percentage for all dental 
appointments at BDH was highest in those travelling greater 
than 100 miles (47%). The DNA rate for the cohort travel-
ling the shortest distance (0–10 miles) was 21%. The lowest 
DNA rate was seen in those travelling 11–20 miles, recorded 
at 0% (Fig. 2).
Regarding previous dental experience, 72% (n = 66) of 
the whole cohort was under the care of a local general den-
tal practitioner, whilst 28% (n = 26) was not registered with 
Table 2  Number of DNAs 
for both the initial dental 
assessment at the BDH and any 
further appointments in relation 
to the distance travelled
Distance to 
clinic (miles)
Patient 
numbers
Received 
initial assess
Number of DNAs 
of initial assess.
Total apts 
at BDH
Total DNAs DNA (%)
0–10 24 15 5 81 17 21
11–20 5 3 0 6 0 0
21–50 29 12 5 41 14 34
51–100 18 8 3 70 19 27
> 100 16 6 2 15 7 47
Fig. 2  The DNA rate for all dental appointments at the BDH for OI 
cohort according to the distance travelled
Fig. 3  Previous dental care 
received by the entire OI cohort 
and then sub-divided into the 
previous dental care received in 
the ‘referred’ and ‘not-referred’ 
groups
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a dentist (Fig. 3). 10% (n = 9) of patients had previously 
received treatment at the BDH before being assessed in 
the OI clinic, the majority of whom presented with dental 
trauma, although one case had gross dental caries coupled 
with poor compliance necessitating treatment under GA. Of 
the 45 who were referred for a tertiary dental assessment, 
58% (n = 26) had a pre-existing general dental practitioner 
(GDP), with 42% (n = 19) having no dentist. Of the 47 not 
referred, 85% (n = 40) received regular dental care from a 
GDP, with only 15% (n = 7) not registered with any dentist 
(Fig. 3).
Of the OI cohort who attended an initial dental assess-
ment in tertiary care (n = 37), 70% (n = 26) had no previ-
ous experience of dental treatment, 14% (n = 5) had res-
torations placed under local anaesthetic, 5% (n = 2) had 
previously undergone GA for extraction of carious teeth 
and 11% (n = 4) had fissure sealants placed on the pos-
terior dentition (Fig. 4). Thirty-four of those assessed in 
tertiary care were over 6 years of age (age by which first 
molars usually have emerged), four of whom had had fis-
sure sealants applied (11%). Further analysis of the 37 
who attended a tertiary care dental appointment indicated 
that all received a full oral hygiene assessment, with 78% 
(n = 29) brushing twice daily and 84% (n = 31) using a 
high-fluoride toothpaste. 95% (n = 35) had radiographs 
taken, caries identified in 41% (n = 15) and 38% (n = 14) 
required extraction under GA for caries. 24% (n = 9) of 
the assessed cohort had dentinogenesis imperfecta (DI), 
although the prevalence was as high as 50% in patients 
with Type III OI. DI was diagnosed on clinical and radio-
graphic analyses alone. Two patients were not included 
as definite DI due to records indicating a subtle appear-
ance of DI for which histological examination of an exfoli-
ated tooth had been proposed for diagnostic clarification, 
although inclusion of those two possible cases would have 
pushed the DI prevalence of 30%. 30% of the assessed 
cohort had malocclusion, with a class III skeletal pattern 
being the most common and all required further ortho-
dontic input.
48% (n = 44) of the whole OI cohort was currently 
receiving bisphosphonate treatment: Pamidronate 30% 
(n = 13) Zoledronic acid 16% (n = 7) and Risedronate 2% 
(n = 1). All were found to be under active dental care: 65% 
at BDH and 35% at their local GDP.
Discussion
We assessed dental health management of a large regional 
OI cohort to explore if it is realistic that all have tertiary 
dental assessment. This real-life experience shows this 
standard is hard to implement: only 49% received a ter-
tiary level dental appointment. This could reflect that 
families may decline suggested additional appointments 
as they already received primary dental care (67%) and 
may not fully appreciate the benefits of more detailed ter-
tiary dental assessment. Geographic factors of distance to 
the tertiary clinic are relevant and influenced whether an 
initial appointment was made and also ultimate attendance 
at appointments arranged: 47% DNA rate in those travel-
ling greater than 100 miles compared to 21% for those 
travelling 0–10 miles. We did not have access to their 
primary dental care records, so cannot comment whether 
those solely under primary dental care had lesser dental 
morbidity or interventions. But we would conjecture that 
the tertiary dental services will have more experience in 
rare children’s skeletal conditions that affect dentition and 
hence have better expertise to identify abnormalities and 
recommend appropriate interventions. Hence, early ter-
tiary dental assessment and intervention allow for optimi-
sation of oral health in OI and prevent the need for surgical 
treatment during bisphosphonate therapy (Trejo and Rauch 
2016).
DI represents a significant dental health problem in 
OI, as COL1A1 and COL1A2 gene mutations result in the 
production of structurally defective dentine inadequately 
attaching to overlying enamel (O’Connell and Marini 
1999). Rapid enamel attrition exposes underlying defective 
dentine (Okawa et al. 2017). We restricted our definition of 
DI to that confirmed on tertiary dental assessment rather 
from medical notes, as mild DI with limited tooth colour 
changes may be missed by medical compared to dental 
professionals (Okawa et al. 2017). 24% of our tertiary level 
dental assessed cohort had DI, similar to the lower end 
of reported prevalence ranges of 30–70% (O’Connell and 
Marini 1999; Barron et al. 2008). Higher DI prevalence 
occurred with more severe OI (Type III 50% and Type IV 
Fig. 4  Previous experience of dental treatment of those who received 
an initial assessment at the BDH (n = 45)
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100%). This reflects that these OI types generally involve 
altered type I collagen structure causing a qualitative 
defect rather than the quantitative impairment in Type I 
OI (Okawa et al. 2017). This highlights the importance of 
a formal dental assessment in tertiary care for all types of 
OI, but especially for those with more severe phenotypes.
DI increases the clinical burden of OI, which supports 
the value of an initial dental assessment in tertiary care for 
all children with OI. Fundamentally, there is rapid tooth 
tissue loss due to the defective dentine structure (Teixeira 
et al. 2008). Caries is one of the most common reason for 
patients with OI seeking dental assessment and treatment 
(Barron et al. 2008; Abukabbos and Ali-Sineedi 2013). 
Dental caries in DI may present later than normal as pain 
is only experienced when the carious lesion is extensive 
because of the pulp chamber obliteration, following the 
rapid deposition of secondary dentine (Okawa et al. 2017). 
We found a 41% (n = 15) caries rate in the assessed cohort 
(n = 37) which is similar to the population prevalence 
of dental caries in UK 8-year-old children (Tsakos et al. 
2013). This is consistent with the current literature report-
ing that primary teeth affected by DI are not more prone 
to dental caries when compared with normal teeth as the 
severe wear is thought to progress faster than the spread 
of dental caries. A limitation of our study is that just over 
50% of our cohort was not assessed at the dental hospi-
tal; so, their prevalence of caries is unknown. The caries 
prevalence could feasibly be less in the assessed cohort. In 
terms of caries prevention, the tertiary dental assessment 
found that most children 6 years or older (30 of 34; 89%) 
had had not yet had fissure sealants applied. This illus-
trates the value-add of tertiary dental input, as primary 
dental practitioners may need guidance that fissure seal-
ants are recommended for children 6 years or older with 
OI, a population with a high risk of caries.
Early detection and intervention are essential for success-
ful DI management (Abukabbos and Ali-Sineedi 2013), as 
deciduous dentition is more frequently affected and exhibits 
more extensive and rapid tooth tissue loss (Sapir and Shapira 
2007). Treatment aims to maintain adequate occlusal height 
and aesthetics, encourage favourable mandibular and max-
illary development and establish favourable conditions for 
permanent dentition eruption (Sapir and Shapira 2007). A 
comprehensive management plan for the deciduous denti-
tion should focus primarily on caries prevention, through 
intensive oral hygiene instruction, fissure sealant placement 
and fluoride application, as well as preserving tooth tissue 
through the placement of preformed metal crowns on pos-
terior teeth (Sapir and Shapira 2007; Abukabbos and Ali-
Sineedi 2013). The literature highlights that regular den-
tal assessment is essential due to the potential for rapidly 
progressive tooth tissue loss (O’Connell and Marini 1999; 
Trejo and Rauch 2016). Late presentation for assessment 
may identify severe attrition with teeth worn down to 
the gingival margin (Barron et al. 2008). Treatment then 
becomes increasingly challenging and complex, highlighting 
the preventative benefit of early expert dental assessment of 
children with OI (Barron et al. 2008).
Oral OI manifestations beyond DI include occlusal 
abnormalities (Rizkallah et al. 2012). Amongst our cohort, 
30% had malocclusion, considerably higher than 3–8% in 
the non-OI population (O’Connell and Marini 1999). It is 
proposed that malocclusion in OI results from inhibition of 
maxillary growth and mandibular prognathism, combined 
with dento-alveolar abnormalities (Rizkallah et al. 2012). 
Malocclusion identified in our patients led to further ortho-
dontic intervention in all cases. Orthodontic management 
in OI is often complex due to the need for orthognathic sur-
gery and lengthy fixed appliance therapy (Rosen et al. 2011). 
Early intervention is beneficial for malocclusion manage-
ment as earlier orthodontic treatment helps reduce treatment 
length (Okawa et al. 2017).
Bisphosphonate therapy has an established role in current 
paediatric OI management (Trejo and Rauch 2016), as seen 
that 48% of our cohort was on treatment. Bisphosphonates 
inhibit osteoclastic bone resorption and reliably increase 
bone mass (Trejo and Rauch 2016). Previous concerns were 
that bisphosphonates may affect dental development through 
reduced resorption of deciduous dentition roots and sur-
rounding bone delaying permanent dentition eruption (Bhatt 
et al. 2014). Animal studies indicated delayed dental devel-
opment (Bradaschia-Correa et al. 2007), whereas recent pae-
diatric OI data are reassuring that bisphosphonate treatment 
normalises rate of dental development in OI (Vuorimies 
et al. 2017). Bisphosphonates may complicate orthodontic 
treatment through osteoclast inhibition decreasing tooth 
movement lengthening treatment time (Iglesias-Linares et al. 
2010). Bisphosphonate Related Osteo-Necrosis of the Jaw 
(BRONJ) is a rare severe oral adverse effect in adults where 
risk factors include malignancy, smoking, radiotherapy, 
alcoholism and malnutrition (Bhatt et al. 2014); moreover, 
large cumulative doses are administered in oncology (Khan 
et al. 2009). No cases of BRONJ have been reported in chil-
dren (Malmgren et al. 2008; Bhatt et al. 2014), although the 
recent single case report of denosumab-associated ONJ in 
oncology underscores the dose-dependent risk and reminds 
us of the continued relevance of dental surveillance for chil-
dren receiving bisphosphonate therapy (Uday et al. 2018).
Reassuringly, all of our cohort receiving bisphospho-
nates were under dental care, although this was tertiary 
level assessment in only half (54%), the remainder under 
GDP. Recommendations for dental management of paediat-
ric OI patients on bisphosphonates are largely extrapolated 
from adult protocols, although bisphosphonate doses and 
jaw anatomy and vasculature do differ between adults and 
children (Bhatt et al. 2014). Recent recommendation from 
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Bhatt et al. for children with OI who may receive bispho-
sphonate therapy (Bhatt et al. 2014) stipulates the follow-
ing: (1) comprehensive dental assessment and elimination 
of dental disease prior to commencing bisphosphonates, (2) 
education on maintenance of meticulous oral hygiene, (3) 
complete all invasive dental work prior to bisphosphonate 
commencement and (4) postpone bisphosphonate therapy 
until the dental health is optimised.
There are extensive data suggesting that the estimated 
incidence of BRONJ following invasive dental procedures 
is increasing in the adult population owing to the increased 
duration of bisphosphonate exposure and more extended 
follow-up periods (Christou 2013). No cases of BRONJ have 
been reported in children but cases may emerge in the future 
as the risk of BRONJ is related to both the cumulative dose 
and duration of bisphosphonate therapy (Christou 2013). 
There are currently no guidelines for the management of 
paediatric patients on bisphosphonates and consequently the 
treatment received is highly variable (Christou 2012). How-
ever, recent recommendations suggest a thorough clinical 
and radiographic dental assessment along with any required 
treatment be provided before the commencement of bis-
phosphonate therapy. A cautious approach to management 
should be adopted due to the future risk of BRONJ through 
cumulative dosing and the continuation of therapy through 
adolescence and into adulthood (Christou 2013).
In accordance with this guidance, 31% required extrac-
tions under GA before bisphosphonate therapy commence-
ment. These GA extractions will have delayed initiating 
bisphosphonates and we postulate that earlier more routine 
tertiary dental assessment could avert these delays. Con-
sequently, optimising their dental health surveillance is an 
integral component of optimising overall OI management.
Conclusion
The study assessed tertiary dental assessments across the 
large OI cohort in the South West of the United Kingdom. 
A notable observation was that many were not referred and 
others then did not attend. Geographic factors of travel dis-
tance to the tertiary centre appear to be an important factor 
in clinician-family decision whether to refer centrally for 
an additional appointment, especially if the child already 
had local dental care in place and also impacted attendance 
rate at arranged appointments. Finding dental pathologies 
in a large proportion of those assessed underscores the rel-
evance of this component of their specialist OI care for all 
children and young people with OI. It was reassuring that all 
patients on bisphosphonates were under regular dental care, 
although only two-thirds at tertiary level. The central role of 
bisphosphonates in current paediatric OI management does 
predicate expert dental vigilance. Awareness of the barriers 
to uptake of tertiary dental care can inform new approaches 
to delivering this dental component of multi-disciplinary 
OI care. Specialised dental assessment does accurately and 
frequently identify significant pathology in children and 
young people with OI, such as caries, DI and malocclusions. 
.Awareness that geographic factors can compromise attend-
ance is important to address by emphasising the clinical 
importance of the role of tertiary dental assessment for all 
patients with OI and, if possible, endeavouring to scheduling 
assessments to coincide with the OI assessments.
Compliance with ethical standards 
Conflict of interest All contributing authors have declared that there is 
no conflict of interest.
Ethical approval This study involved human participants and was con-
ducted in accordance with the ethical standards of the institutional 
research committee and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards.
Human and animal participants This manuscript involved human par-
ticipants.
Informed consent This service evaluation was a retrospective note 
review of anonymised data and did not entail individual participant 
consent process. Informed consent was obtained from all participants.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
Appendix 1: Search words used for assessing 
the electronic dental records
– Osteogenesis imperfecta (OI)
– Dentinogenesis imperfecta (DI)
– Bisphosphonate(s)
– Dental assessment
– General dental practitioner (GDP)
– Caries
– Bitewing radiographs
– Fissure sealant(s)
– Extraction
– General anaesthetic (GA)
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